Inhibitors of the ERCC1/XPA interaction with activity against colorectal and lung cancer cell lines have been reported [24, 25] and an in silico drug screen identified compounds that can disrupt ERCC1-XPF complex stability in cell lysates [26]. The gene discussed is ERCC1; the disease is lung carcinoma.